BN Business News
Add your company to Business Communicator →

Business · 08/08/2024Updated: 10/17/2026 · 1 min read

Flamingo Pharmaceuticals Ltd. Faces FDA Proposal to Withdraw Approval of Two ANDAs

Summary

The FDA is proposing to withdraw approval of two Abbreviated New Drug Applications (ANDAs) held by Flamingo Pharmaceuticals Ltd. due to repeated failure to file required annual reports, and is offering the company an opportunity to request a hearing on the proposal.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →